Clinical Trials
22 trialsNCT03905889 2024-06-25
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Brown University
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT00520533 2022-10-12
Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
Ludwig Institute for Cancer Research
Phase 1 Terminated
NCT01061411 2022-08-05
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01258348 2019-01-10
A Phase 1b Trial in Patients With Renal Cell Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02386111 2018-07-26
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Celldex Therapeutics
Phase 1 Terminated
NCT00499135 2017-10-10
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00694096 2015-12-01
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
University of Utah
Phase 1 Completed
NCT01122615 2015-11-18
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00747305 2015-10-22
Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Medical University of South Carolina
Phase 1 Terminated
NCT00788060 2015-02-16
Rad/Sutent
Duke University
Phase 1 Completed
NCT00631527 2015-01-29
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01243359 2014-04-02
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
National Cancer Institute (NCI)
Phase 1 Completed
NCT00890747 2014-03-17
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00399152 2014-02-19
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
AEterna Zentaris
Phase 1 Completed
NCT00790595 2012-07-31
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00372853 2012-06-06
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
AstraZeneca
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00422344 2010-02-26
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00421512 2008-11-11
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed